Gene Therapy Collaboration and Licensing Deals 2016-2024


Gene Therapy Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
May 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of gene therapy deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 740 gene therapy deals announced since 2016 including financial terms where available including links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of gene therapy dealmaking. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016.

Chapter 3 provides an overview of the leading gene therapy deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in gene therapy dealmaking with a brief summary followed by a comprehensive listing of gene therapy deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of gene therapy deals signed and announced since Jan 2016, where a contract document is available in the public domain. 

Chapter 6 provides a comprehensive and detailed review of gene therapy partnering deals signed and announced since Jan 2016. The chapter is organized by specific gene therapy technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in gene therapy deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Gene Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse gene therapy collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Report scope

Gene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies worldwide.

Gene Therapy Collaboration and Licensing Deals includes:
•    Trends in gene therapy dealmaking in the biopharma industry
•    Directory of gene therapy deal records covering pharmaceutical and biotechnology
•    The leading gene therapy deals by value
•    Most active gene therapy licensing dealmakers

Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

•    What are the precise rights granted or optioned?
•    What is actually granted by the agreement to the partner company?
•    What exclusivity is granted?
•    What is the payment structure for the deal?
•    How are sales and payments audited?
•    What is the deal term?
•    How are the key terms of the agreement defined?
•    How are IPRs handled and owned?
•    Who is responsible for commercialization?
•    Who is responsible for development, supply, and manufacture?
•    How is confidentiality and publication managed?
•    How are disputes to be resolved?
•    Under what conditions can the deal be terminated?
•    What happens when there is a change of ownership?
•    What sublicensing and subcontracting provisions have been agreed?
•    Which boilerplate clauses does the company insist upon?
•    Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
•    Which jurisdiction does the company insist upon for agreement law?

Gene Therapy Collaboration and Licensing Deals provides the reader with the following key benefits:

•    Understand deal trends since 2016
•    Browse gene therapy collaboration and licensing deals
•    Benchmark analysis – identify market value of transactions
•    Financials terms - upfront, milestone, royalties
•    Directory of deals by company A-Z, deal type and therapy area
•    Leading deals by value
•    Most active dealmakers
•    Identify assets and deal terms for each transaction
•    Access contract documents - insights into deal structures
•    Due diligence - assess suitability of your proposed deal terms for partner companies
•    Save hundreds of hours of research time

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in gene therapy dealmaking
2.1. Introduction
2.2. Gene therapy deals over the years
2.3. Most active gene therapy dealmakers
2.4. Gene therapy deals by deal type
2.5. Gene therapy deals by therapy area
2.6. Gene therapy deals by industry sector
2.7. Deal terms for gene therapy deals
2.7.1 Gene therapy deals headline values
2.7.2 Gene therapy deal upfront payments
2.7.3 Gene therapy deal milestone payments
2.7.4 Gene therapy royalty rates

Chapter 3 – Leading gene therapy deals
3.1. Introduction
3.2. Top gene therapy deals by value

Chapter 4 – Most active gene therapy dealmakers
4.1. Introduction
4.2. Most active gene therapy dealmakers
4.3. Most active gene therapy deals company profiles

Chapter 5 – Gene therapy contracts dealmaking directory
5.1. Introduction
5.2. Gene therapy contracts dealmaking directory

Chapter 6 – Gene therapy dealmaking by technology type

Deal directory

Deal directory – Gene therapy deals by company A-Z
Deal directory – Gene therapy deals by deal type
Deal directory – Gene therapy deals by therapy area

Deal type definitions

About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Gene therapy deals since 2016
Figure 2: Active gene therapy dealmaking activity – 2016 - 2024
Figure 3: Gene therapy deals by deal type since 2016
Figure 4: Gene therapy deals by therapy area since 2016
Figure 5: Gene therapy deals by industry sector since 2016
Figure 6: Gene therapy deals with a headline value
Figure 7: Gene therapy deals with an upfront value
Figure 8: Gene therapy deals with a milestone value
Figure 9: Gene therapy deals with a royalty rate value
Figure 10: Top gene therapy deals by value since 2016
Figure 11: Most active gene therapy dealmakers 2016 - 2024
Figure 12: Gene therapy deals by technology type since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2A, 2seventy bio, 3T Biosciences, 4D Molecular Therapeutics, AavantiBio, AAVnerGene, Abbvie, Abby Grace Foundation, Abeona Therapeutics, Abintus Bio, ABL Bio, Abzena, Academy of Military Medical Sciences (China), Accelerator for Technological Research in Genomic Therapies, Accenture, aCGT Vector, Actinium Pharmaceuticals, Acuitas Therapeutics, Adaptive Phage Therapeutics, Adolore Biotherapeutics, Advanced BioScience Laboratories, Adverum Biotechnologies, Aegis Life, Aevitas Therapeutics, Affini-T Therapeutics, Affinia Therapeutics, AffyXell Therapeutics, AGC Biologics, Agilis Biotherapeutics, Akouos, Alaunos Therapeutics, Albumedix, Alcyone Lifesciences, Alder Biopharmaceuticals, Aldevron, Allen Institute for Brain Science, Alliance for Cancer Gene Therapy, Alliance for Regenerative Medicine, Allogene Therapeutics, AllStripes, Almirall, Alnylam Pharmaceuticals, Alpha Teknova, Altimmune, Amarna Therapeutics, Ambys Medicines, American Association of Neuromuscular & Electrodiagnostic Medicine, American Gene Technologies, American Society of Gene and Cell Therapy, Amicus Therapeutics, AmplifyBio, AmpliPhi Biosciences, Amryt Pharma, Analog Devices, Anew Medical, Angionetics, Annapurna Therapeutics, Apic Bio, Apollo Therapeutics, Applied DNA Sciences, Applied Genetic Technologies, Applied StemCell, Aptuit, Arbor Biotechnologies, Armata Pharmaceuticals, Armatus Bio, Aruvant Sciences, Ascenion, ASC Therapeutics, Asimov, Asklepios Biopharmaceutical, Astellas Pharma, Astellas Pharma US, AstraZeneca, Athebio, Athenex, ATMPS, Auburn University, Audentes Therapeutics, Autodesk, Avacta, Avance Biosciences, Avantor, Avectas, Avellino Labs, AveXis, Avid Bioservices, Avista Therapeutics, Avita Therapeutics, Avrobio, Axovant Gene Therapies, Axovia Therapeutics, Banner MD Anderson Cancer Center, Bayer, Baylor College, Beam Therapeutics, Benitec Biopharma, Bennu Pharmaceuticals, Berkeley Lights, Bespoke Gene Therapy Consortium, Be The Match BioTherapies, Bharat Biotech, BIA Separations, Bicycle Therapeutics, Bill and Melinda Gates Foundation, BIOASTER, BioCardia, BioCentriq, BioComo, BioCure, Biogen, Bioharmony Therapeutics, BioInvent, BioLife Solutions, BioMap, BioMarin Pharmaceutical, Biomedical Advanced Research and Development Authority, BiomX, Bionic Sight, BionX Medical Technologies, Biophage Pharma, BioSpherix, Biotechnology and Biological Sciences Research Council (BBSRC), Biotheus, BioVectra, Bioverativ, Bird Foundation, Blackstone, Blood Centers of America, Bluebird Bio, Blueprint Genetics, Boehringer Ingelheim, Bpifrance, Brain Research Through Advancing Innovative NeurotechnologiesInitiative, Brammer Bio, BriaCell Therapeutics, BridgeBio Pharma, Bristol-Myers Squibb, BRL Medicine, Broad Institute, Brooklyn ImmunoTherapeutics, Cabaletta Bio, Calidi Biotherapeutics, California Institute for Regenerative Medicine, California Institute of Technology, Calimmune, CAMP4 Therapeutics, CANbridge Pharmaceuticals, Cancer Research Institute, Capsida Biotherapeutics, Capsigen, Captivate Bio, CARB-X, Caring Cross, Carisma Therapeutics, Casebia Therapeutics, Case Western Reserve University, Castle Creek Biosciences, Catalent, CDISC, Celgene, Cell and Gene Therapy Catapult, Cellares, Cellevolve Bio, CellGenix, Cell Mogrify, Cell One Partners, Cell Point, CellPoint, Center for Breakthrough Medicines, Center for Genomic Regulation, Centre for Commercialization of Regenerative Medicine (CCRM), Cevec Pharmaceuticals, CGT Global, Charles River Laboratories, Children's Hospital Boston, Children's Hospital of Philadelphia, Children's Hospital of Pittsburgh, Children's Medical Research Institute, Children's Research Institute, Chinagene Tech, Cincinnati Children’s Hospital Medical Center, City of Hope, ClearPoint Neuro, Clearside Biomedical, Cleveland Clinic, CMT Research Foundation, Coalition for Epidemic Preparedness Innovations, Coave Therapeutics, Cobra Biologics, CODA Biotherapeutics, Code Biotherapeutics, Codexis, Codiak BioSciences, Cognate BioServices, Columbia University, CombiGene, ContraFect, Copernicus Therapeutics, Cornell University, CPI International, CRISPR Therapeutics, CryoPort, CSafe Global, CSL, CSL Behring, Cure Duchenne, Cure Genetics, Curigin, Cyagen Biosciences, Cyprium Therapeutics, Cystic Fibrosis Foundation, Cytiva, Cytoo, Cytovance Biologics, DAAN Bio Therapeutics, Daewoong Pharmaceutical, Daiichi Sankyo, Danaher, DanausGT Biotechnology, Dartmouth College, DCM, Decibel Therapeutics, Deep Science Ventures, Deerfield Management, Defense Advanced Research Projects Agency, Defense Health Agency (US), DefiniGEN, Denali Therapeutics, Department of Defense, Department of Health and Human Services, Desktop Genetics, Dimension Therapeutics, DiNAQOR, DNA Script, Dr. Reddy's Laboratories, DTx Pharma, Duke University, Dyno Therapeutics, Editas Medicine, EditForce, Eikonoklastes Therapeutics, ElevateBio, Eligo Bioscience, Eli Lilly, Embleema, Emory University, EnBiotix, Enesi Pharma, Enlivex, Ensoma, Entos Pharmaceuticals, ERS Genomics, Eunice Kennedy Shriver Institute of Child Health and Human Development, Eureka Therapeutics, European Union, Everads Therapy, EverCell Bio, Eversana, Evogene, Evonetix, Evotec, Evox Therapeutics, Evozyne, Exothera, Expression Therapeutics, F1 Oncology, Facial Pain Research Foundation, Factor Bioscience, Federal Ministry of Education and Research (BMBF), Felix Biotechnology, FerGene, Ferring Pharmaceuticals, Fibrocell Science, FIT Biotech, FKD Therapies, FloDesign Sonics, Florabio, Fondazione San Raffaele, Fondazione Telethon, Food and Drug Administration (FDA), Forcefield Therapeutics, Forge Biologics, Form Bio, Fortress Biotech, Forty Seven, Foundation Fighting Blindness, Foundation to Fight H-ABC, Frametact, Freeline Therapeutics, Fresenius Kabi Pharmaceuticals, Friedreichs Ataxia Research Alliance, Fujifilm Diosynth Biotechnologies, Fulcrum Therapeutics, Fundacion Progreso y Salud, G-Con, GE Healthcare, Gen, Gen9, GenCure, GeneCraft, GenEdit, GeneFab, Genelux, Genenta Science, Genentech, GeneQuine Biotherapeutics, Generation Bio, Generation Biotech, Genethon, Genetic Information Research Institute, Genevant Sciences, Genezen, GenKOre, Gennao Bio, Genome Medical, Genosera, Genovis, Genpharm, Genprex, Gensaic, GenScript Biotech, GenScript ProBio, GenStem Therapeutics, GentiBio, Genzyme, George Washington University, GeoVax, Germfree, Gilead Sciences, Ginkgo BioWorks, GlycoBac, Gradalis, Graphite Bio, Great Ormond Street Hospital (GOSH), Greenlight Biosciences, Gritstone Bio, GSK, Gyroscope Therapeutics, Hadassah Medical Center, HaemaLogiX, Hansa Biopharma, Harvard University, Hebrew University of Jerusalem, HekaBio, Hemera Biosciences, Hitech Health, Homology Medicines, Horama, Horizon Discovery, Horizon Europe, Hoth Therapeutics, Huapont Pharma, Humanigen, Hunterian Medicine, Hypertrust, IASO Biotherapeutics, Iaso Pharmaceuticals, Iaso Therapeutics, Icahn School of Medicine at Mount Sinai, iECURE, IGEA Clinical Biophysics, Ikarovec, ImmunityBio, ImmVira, Imperial Innovations, Imugene, Indee Labs, InnoBation, Innovate UK, Innovent Biologics, InProTher, Inscripta, Institute of Child Health, Institute of Molecular and Clinical Ophthalmology Basel, Institute of Neurodegenerative Diseases, Instituto de Biologia Experimental e Tecnológica, Institut Pasteur, Integral Molecular, Integra Therapeutics, Intellia Therapeutics, Interbiome, International AIDS Vaccine Initiative, Intralytix, Intrexon, iNtRON Biotechnology, Invitae, Ion Channel Innovations, Ionis Pharmaceuticals, iTolerance, Iveric Bio, iVexSol, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Jasper Therapeutics, JCR Pharmaceuticals, Jenner Institute, Jiangsu Hengrui Medicine, Johns Hopkins University, Johnson & Johnson Innovation, JSR, Juniper Biologics, Juno Therapeutics, Juventas Therapeutics, Kadimastem, KaliVir Immunotherapeutics, Kate Therapeutics, Kelonia Therapeutics, Kiromic Biopharma, Kissei Pharmaceutical, Kite Pharma, Kogenix, Kolon Life Science, Kriya Therapeutics, KromaTiD, Kyverna Therapeutics, LabConnect, Laboratoires Thea, Laboratory Corporation of America, Lacerta Therapeutics, Lantheus Holding, Leiden University, Leidos, Lesaffre, Leukocare, LEXEO Therapeutics, Ligandal, Locana, Locus Biosciences, LogicBio Therapeutics, Lonza, Lupagen, Lysogene, Magenta Therapeutics, Mammoth Biosciences, Marken, Maryland Stem Cell Research Fund, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Mass General Brigham, Matica Biotechnology, Mawson Infrastructure, Max-Delbruck Center for Molecular Medicine, Maxcyte, Mayo Clinic, Mayo Clinical Ventures, McKesson, McMaster University, MD Anderson Cancer Center, MDA Venture Philanthropy, Medac, Medgenics, Medical University of South Carolina, MediciNova, Medifocus, MediGene, MedImmune, MED Institute, MeiraGTx, Metagenomi, Michael J Fox Foundation, Microsoft, Mie University, MilliporeSigma, MiNA Therapeutics, Mirum Pharmaceuticals, Mission Bio, Mitsubishi Tanabe Pharma, Modalis Therapeutics, Moderna, Moligo Technologies, MolMed, Morgenesis, MorphoSys, Mosaic ImmunoEngineering, Mount Sinai Health System, MSD, Muscular Dystrophy Association, Mustang Bio, Myonexus Therapeutics, Myrtelle, Nanommune, Nanoscope Therapeutics, Nanotronics Health, NantKwest, NantOmics, NATA, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Eye Institute, National Heart, Lung and Blood Institute, National Human Genome Research Institute, National Institute for Innovation in Manufacturing Biopharmaceuticals, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Organization for Rare Disorders, National Research Council Canada, National Resilience, National Science Foundation, National Taiwan University Hospital, Nationwide Children’s Hospital, Navy Medical Research Centre, NEC, NecstGen, Neo Gene Pharm, NeuExcell, Neuracle Genetics, Neurimmune Therapeutics, Neurochase, Neurocrine Biosciences, Neurogene, Neurophth Therapeutics, NewBiologix, New Jersey Innovation Institute, Newsoara Biopharma, Next Generation Manufacturing Canada, Nightstar Therapeutics, Nippon Shinyaku, Nkarta Therapeutics, Noga Therapeutics, North Carolina State University, Northeastern University, Northern Biomedical Research, Northern RNA, Northwestern University, Novartis, Novartis Institutes for BioMedical Research, Novasep, Novellus Biopharma, Novo Nordisk, Nucleus Biologics, NysnoBio, NYU Langone Medical Center, Obio, Octomera, Ocugen, Oculogenex, Odylia Therapeutics, OmniaBio, Oncolys BioPharma, OncoSec Medical, Ophthotech, Optimeos Life Sciences, Opus Genetics, Orchard Therapeutics, Oregon Health Sciences University, Oregon National Primate Research Center, Orgenesis, Ori Biotech, Oswaldo Cruz Foundation (Fiocruz), Otsuka, Ovid Therapeutics, Oxford BioMedica, Oxford Genetics, Oxgene, Oyster Point Pharma, Pall Corporation, Panion, Papyrus Therapeutics, Paragon Bioservices, Parent Project Muscular Dystrophy, Passage Bio, Passport Food Safety Solutions, Paul Ehrlich Institute, PaxVax, Perelman School of Medicine, PersonGen BioTherapeutics, Peter MacCallum Cancer Institute, Pfizer, Phagelux, PharmaCell, Pherecydes Pharma, Phibro Animal Health, PhoreMost, PlantArcBio, PlasmidFactory, Plasticell, Plastomics, Polyplus Transfection, Population Diagnostics, Poseida Therapeutics, Precigen, Precision BioSciences, PrecisionLife, Precision NanoSystems, Precision Virologics, Predictive Oncology, Pregene Biopharma, Prevail Therapeutics, PreveCeutical Medical, Prime Medicine, ProteoNic, Provecs Medical, PsiOxus Therapeutics, PTC Therapeutics, Purespring Therapeutics, rAAVen Therapeutics, Ray Therapeutics, ReCode Therapeutics, Refreshgene Therapeutics, Regeneron Pharmaceuticals, Regenxbio, ReiThera, Rejuvenate Bio, Remedium Bio, Renova Therapeutics, RenovoRx, Rentschler Biotechnologie, Rescue Hearing, Research Development Foundation, Resilience, RetroSense Therapeutics, Reyon Pharmaceuticals, Roche, Rocket Pharmaceuticals, Roivant Sciences, Rokote Laboratories, RoosterBio, Russian Direct Investment Fund, Rznomics, Saint Louis University, Sana Biotechnology, Sangamo Therapeutics, Sanofi, Santen Pharmaceutical, Santhera Pharmaceuticals, Sant Joan de Déu-Barcelona Children’s Hospital, Sapreme Technologies, Sarepta Therapeutics, Sartorius, Sartorius Stedim Biotech, SATT Conectus Alsace, Scenic Biotech, Schepens Eye Research Institute, Scopus BioPharma, Scribe Therapeutics, Scriptr Global, SCTbio, Seattle Children's Hospital, Seattle Children's Therapeutics, Seattle Childrens Research Institute, Seelos Therapeutics, Selecta Biosciences, Sensei Biotherapeutics, Sensorion, Senti Biosciences, SeQure Dx, Sexton Biotechnologies, Shape Therapeutics, Shenzhen Yuanxing Bio-Pharm Science & Technology, Shinshu University, Sino Biological, Sio Gene Therapies, Sirion Biotech, Sirtex Medical, SiSaf, Skyline Therapeutics, SmartPharm Therapeutics, Solid Biosciences, Solve GNE, SonoThera, SparingVision, Spark Therapeutics, SpliceBio, Spooner Girls Foundation, SpringWorks Therapeutics, SQZ Biotech, St. Jude Children's Research Hospital, Stanford University, StemCardia, St Jude Medical, StrideBio, Strm.Bio, Summit Biosciences, SunTerra Biotechnology, Suzhou Porton Advanced Solutions, SwanBio Therapeutics, Symbiosis, Symvivo, Synplogen, Synpromics, Synthego, T-TOP Clinical Research, Takeda Pharmaceutical, Talee Bio, Tamid Bio, Tantu Therapeutics, Targovax, Taysha Gene Therapies, TeamedOn International, Team Sanfilippo, Terumo Blood and Cell Technologies, Tetherex Pharmaceuticals, Teva Pharmaceutical Industries, Tevard Biosciences, Texas A&M Health Science Center, Texcell, TFF Pharmaceuticals, The Cyprus Institute of Neurology and Genetics, The Native Antigen Company, The Parker Institute For Cancer Immunotherapy, Theracell, Theravectys, Theriva Biologics, Thermo Fisher Scientific, Tianjin CanSino Biotechnology, TILT Biotherapeutics, TissueGene, Tome Biosciences, Toshiba, Touchlight, Trakcel, Transgene, Trieza Therapeutics, Triumvira Immunologics, Tufts University, Turnstone Biologics, Twist Bioscience, Tyris Therapeutics, UCB, UCL Business, UK Cystic Fibrosis Gene Therapy Consortium, Ulster University, Ultragenyx Pharmaceuticals, Umoja Biopharma, UniQuest, UniQure, Univercells, University College Dublin, University College London, University of Alabama, University of Barcelona, University of Basel, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Colorado, University of Eastern Finland, University of Edinburgh, University of Florida, University of Florida Research Foundation, University of Helsinki, University of Iowa, University of Kansas, University of Leeds, University of Manchester, University of Massachusetts, University of Massachusetts Medical School, University of Miami, University of Minnesota, University of Missouri, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, University of Pittsburgh Medical Center, University of Texas, University of Texas Southwestern Medical Center, University of Washington, University of Western Sydney, University of Wisconsin-Madison, Urovant Sciences, US Army, UT Southwestern Medical Center, Vaccinex, Vaccitech, Valo Therapeutics, Vaxalto Biotherapeutics, Vectalys, Vector BioMed, Vector BioPharma, VectorBuilder, VectorY Therapeutics, Verismo Therapeutics, Vertex Pharmaceuticals, Vesigen Therapeutics, VIB, Vifor-Fresenius Medical Care Renal Pharma, Vigene Biosciences, ViGeneron, Vineti, Viralgen, Vir Biotechnology, Virginia Commonwealth University, Virica Biotech, VIVEbiotech, Vivet Therapeutics, Voyager Therapeutics, Vycellix, Vyriad, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, Weill Cornell Medical College, Weizmann Institute, Werum IT Solutions, Westmead Institute for Medical Research, WhiteLab Genomics, WIRB-Copernicus Group, WuXi Advanced Therapies, Wuxi Apptec Laboratory Services, Xcell Biosciences, Xencor, Xyphos Biosciences, Y-Biologics, Yale Cancer Center, Yale University, Yeda Research and Development Company, Yinjia Biosciences, Yissum Research Development, Yposkesi, Ziopharm Oncology, Zogenix

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.